Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.

Abstract

BACKGROUND:

The present study aimed to clarify the efficacy and safety of ramucirumab in a real-world setting, including patients who experienced two or more systemic treatments or whose hepatic reserve was deteriorated.

METHODS:

In total, 79 patients with hepatocellular carcinoma (HCC) from 14 institutes throughout Japan were retrospectively analyzed. The response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and AEs were recorded according to the Common Terminology Criteria for AEs (CTCAE) version 5.0.

RESULTS:

Median overall survival (OS) in the total cohort was 7.5 months (m). Median OS was 8.8 m in patients who were administered ramucirumab as a second-line treatment, while it was 7.3 m in third- or later-line treatment. Progression-free survival rates in the second- and third- or later-line therapies were 3.2 m and 3.2 m, respectively. The disease control rate (DCR) in the study was 43%. There were no statistically significant differences in DCR between the treatment courses. Regarding adverse events (AEs), the development of ascites was observed significantly more frequently in modified albumin-bilirubin (mALBI) 2b/3 patients than in mALBI 1/2a patients (54.5% vs. 25.0%, p = 0.03).

CONCLUSIONS:

Ramucirumab is useful as a second-line therapy and feasible as a third- or later-line treatment for HCC.

• Authors: Yutaka Yasui, Masayuki Kurosaki, Kaoru Tsuchiya, Yuka Hayakawa, Chitomi Hasebe, Masami Abe, Chikara Ogawa, Kouji Joko, Hironori Ochi, Toshifumi Tada, Shinichiro Nakamura, Koichiro Furuta, Hiroyuki Kimura, Keiji Tsuji, Yuji Kojima, Takehiro Akahane, Takashi Tamada, Yasushi Uchida, Masahiko Kondo, Akeri Mitsuda, Namiki Izumi, Japanese Red Cross Liver Study Group
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 12 (Jun 16 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 35740647 (Publication Type: Journal Article)